United States v. Peter Navarro

United States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT Argued December 18, 2025 Decided July 21, 2026 No. 24-3006 UNITED STATES OF AMERICA, APPELLEE v. PETER K. NAVARRO, APPELLANT Appeal from the United States District Court for the District of Columbia (No. 1:22-cr-00200-1) Stanley M. Brand argued the cause for appellant. With him on the briefs were John S. Irving IV and John P. Rowley III. Kelly B. McClanahan was on the brief for amici curiae Heidi Kitrosser, et al. in support of affirmance. Before: MILLETT, PILLARD, and CHILDS, Circuit Judges. Opinion for the Court filed by Circuit Judge MILLETT.  2 MILLETT, Circuit Judge: In 2021, Peter K. Navarro, a former aide to then-former President Donald J. Trump, published a book about his stint in politics. In that book and in promotional interviews, Dr. Navarro took credit for devising a plan to “leverage” the Vice President’s authority under the Electoral Count Act of 1887 to “delay certification” of the results of the 2020 presidential election on January 6, 2021. Dr. Navarro’s public statements caught the attention of the U.S. House of Representatives’ Select Committee to Investigate the January 6th Attack on the U.S. Capitol. The Select Committee sent a subpoena to Dr. Navarro that sought documents related to his book and public statements and that ordered him to appear for a deposition on those topics. Dr. Navarro claimed executive privilege before even seeing the subpoena and refused to turn over documents, appear for his deposition, or engage with the Select Committee’s efforts to accommodate his privilege claim. After the deadline for compliance passed, the House of Representatives voted to hold Dr. Navarro in contempt, and a federal grand jury indicted Dr. Navarro on two counts of contempt of Congress. Dr. Navarro moved to dismiss the indictment on the ground that President Trump had invoked executive privilege. After an evidentiary hearing, the district court concluded that no such invocation of privilege had occurred and declined to dismiss the indictment. The district court also granted the government’s motion in limine to preclude Dr. Navarro from arguing to the jury that he mistakenly believed he was not required to respond to the Select Committee’s subpoena. A jury subsequently found Dr. Navarro guilty on both counts of contempt. Dr. Navarro appealed. We affirm.  3 I A Congress’s “power to secure needed information” through subpoenas “has long been treated as an attribute of the power to legislate.” McGrain v. Daugherty, 273 U.S. 135, 161 (1927). “Without information, Congress would be shooting in the dark, unable to legislate ‘wisely or effectively.’” Trump v. Mazars USA, LLP, 140 S. Ct. 2019, 2031 (2020) (quoting McGrain, 273 U.S. at 175). For that reason, both “the power of inquiry” and “process to enforce it” are “essential and appropriate auxiliar[ies] to the legislative function.” McGrain, 273 U.S. at 174; see also Quinn v. United States, 349 U.S. 155, 160–161 (1955) (“Without the power to investigate—including of course the authority to compel testimony, either through its own processes or through judicial trial—Congress could be seriously handicapped in its efforts to exercise its constitutional function[.]”) (footnotes omitted). Each House of Congress can delegate its full subpoena power to “committees and subcommittees[.]” Watkins v. United States, 354 U.S. 178, 200–201 (1957). The House of Representatives made such a delegation to the January 6th Select Committee. See H.R. Res. 503, 117th Cong., 1st Sess. § 5(c)(4) (2021). Federal law mandates compliance with congressional subpoenas. Under Section 192 of Title 2, “[e]very person” subpoenaed “by the authority of either House of Congress to give testimony or to produce papers” on a “matter under inquiry” before “any committee of either House” must comply with that subpoena. 2 U.S.C. § 192. Any person who “willfully makes default” on the subpoena or, “having appeared, refuses to answer any question pertinent to the  4 question under inquiry, shall be deemed guilty of a misdemeanor[.]” Id. A congressional committee may refer a report finding a witness’s default to the full House or Senate. 2 U.S.C. § 194. If the full body approves a contempt citation, the Speaker of the House or President of the Senate, as the case may be, must refer that citation to the appropriate United States Attorney’s Office for prosecution. Id. B Recipients of congressional subpoenas “retain common law and constitutional privileges” against governmental demands for the disclosure of requested information. Mazars, 140 S. Ct. at 2032. As relevant here, a subpoena recipient may resist the disclosure of specific “governmental communications protected by executive privilege.” Id. “Executive privilege is an extraordinary assertion of power ‘not to be lightly invoked.’” Cheney v. United States Dist. Ct. for D.C., 542 U.S. 367, 389 (2004) (quoting United States v. Reynolds, 345 U.S. 1, 7 (1953)). This case concerns two types of executive privileges: the presidential communications privilege and testimonial immunity. This opinion uses the term “executive privilege” to refer to both. 1 The presidential communications privilege is the “canonical form of executive privilege[.]” Trump v. Thompson, 20 F.4th 10, 25 (D.C. Cir. 2021). It permits the President to shield from disclosure “documents or other materials that reflect presidential decisionmaking and deliberations and that the President believes should remain  5 confidential.” In re Sealed Case, 121 F.3d 729, 744 (D.C. Cir. 1997). The presidential communications privilege arises implicitly “from the supremacy of the Executive Branch within its assigned area of constitutional responsibilities[.]” Nixon v. Administrator of Gen. Servs., 433 U.S. 425, 447 (1977) (“Nixon v. GSA”). The confidentiality afforded by the presidential communications privilege protects “the public interest in candid, objective, and even blunt or harsh opinions in Presidential decisionmaking.” United States v. Nixon, 418 U.S. 683, 708 (1974). Without such protection, “[h]uman experience teaches that those who expect public dissemination of their remarks may well temper candor with a concern for appearances and for their own interests to the detriment of the decisionmaking process.” Id. at 705. In addition, because that confidentiality would have little value if it dissolved the moment a president’s time in office ended, the presidential communications privilege “survives the individual President’s tenure.” Nixon v. GSA, 433 U.S. at 449. The presidential communications privilege, however, is not absolute. See Trump v. United States, 144 S. Ct. 2312, 2330 (2024). Its protection is only “presumptive[,]” United States v. Nixon, 418 U.S. at 708, and “qualified[,]” subject to being outweighed by competing interests, Thomspon, 20 F.4th at 26. The privilege’s protection “may be overcome by ‘a strong showing of need by another institution of government[.]’” Thompson, 20 F.4th at 26 (alteration in original) (quoting Senate Select Comm. on Presidential Campaign Activity v. Nixon, 498 F.2d 725, 730 (D.C. Cir. 1974) (en banc)). And it applies narrowly to “records solicited and received by the President or the President’s immediate White House advisers who have broad and significant responsibility for advising the President.” Id. at 25–26 (formatting modified); see also  6 Mazars, 140 S. Ct. at 2032–2033 (declining to “transplant that protection root and branch to * * * [information] which by definition does not implicate sensitive Executive branch deliberations”). 2 This case also involves a claim of “testimonial immunity.” No court has ever recognized this privilege. The Office of Legal Counsel (“OLC”) has issued multiple opinions on the topic in which it reasons that the President’s “immediate advisers are absolutely immune from testimonial compulsion by a Congressional committee on matters related to their official duties” during their tenure. Testimonial Immunity Before Congress of the Former Counsel to the President, 43 Op. O.L.C. 108, 110 (2019) (“Testimonial Immunity”) (quotation marks omitted); see also Congressional Oversight of the White House, 45 Op. O.L.C. ---, 2021 WL 222744, at *35 (Jan. 8, 2021); Memorandum from William H. Rehnquist, Assistant Att’y Gen., Off. of Legal Counsel, to John D. Ehrlichman, Assistant to the President for Domestic Affs., Re: Power of Congressional Committee to Compel Appearance or Testimony of “White House Staff” 7 (Feb. 5, 1971), https://perma.cc/TK7J-WHKH (“[T]hose who customarily meet with the President on a regular or frequent basis” cannot “be compelled to appear before a congressional committee.”). 1 0F OLC has further opined that this testimonial immunity “continues after” an adviser leaves the White House such that the sitting “President may lawfully direct [a former adviser] not 1 This court referenced, but did not ultimately address, testimonial immunity in Committee on the Judiciary, U.S. House of Representatives v. McGahn, 951 F.3d 510, 518 (D.C. Cir. 2020), rev’d en banc, 968 F.3d 755 (D.C. Cir. 2020), on reh’g, 973 F.3d 121 (D.C. Cir. 2020).  7 to appear in response to” a congressional subpoena. Testimonial Immunity, 43 Op. O.L.C. at 123, 128. But when a former President directs a former adviser not to testify, that adviser enjoys only “a qualified, rather than absolute, testimonial immunity.” See Statement of Interest of the United States at 8, Meadows v. Pelosi, 639 F. Supp. 3d 62 (D.D.C. 2022) (No. 21-cv-3217) (citing Testimonial Immunity, 43 Op. O.L.C. at 110–120). For purposes of this appeal, we assume without deciding that testimonial immunity is a valid privilege and that it can apply when invoked by a former President. II A On January 6, 2021, both Houses of Congress convened in a joint session to certify the votes of the Electoral College in the 2020 presidential election. During that session, a mob of rioters overwhelmed the security perimeter around the Capitol, breached the Capitol itself, and delayed the certification process. See Fischer v. United States, 144 S. Ct. 2176, 2182 (2024); Thompson, 20 F.4th at 17–18. Six months later, the House of Representatives adopted House Resolution 503 and established the U.S. House of Representatives Select Committee to Investigate the January 6th Attack on the U.S. Capitol. H.R. Res. 503, 117th Cong., 1st Sess. (2021). Resolution 503 directed the Select Committee to “investigate and report upon the facts, circumstances, and causes” of the events of January 6th. Id. § 3(1). Resolution 503 also empowered the Chairman of the Select Committee to issue subpoenas for relevant documents and testimony. Id. § 5(c)(4).  8 From 2017 to 2021, Peter Navarro served in various roles in the first Trump administration as a self-described “senior White House adviser[.]” J.A. 394. After the House of Representatives impeached then-President Trump on January 13, 2021, Dr. Navarro published the “Navarro Report”—a three-volume compendium designed as an “evidentiary handbook” for the Senate’s impending impeachment trial that purported to show that the 2020 election results were “the poisonous fruit of widespread fraud[.]” J.A. 397–398. Dr. Navarro publicly promoted the Report and discussed his findings “in his capacity as a private citizen[,]” not as a government employee. J.A. 809. In November 2021, having left the government, Dr. Navarro published a book titled In Trump Time: My Journal of America’s Plague Year. In those pages, Dr. Navarro claimed to have devised a “strategy called the Green Bay Sweep which sought to leverage Vice President Mike Pence’s constitutional power under the Electoral Count Act of 1887” to delay Congress’s certification of the Electoral College vote on January 6th. J.A. 401. In interviews promoting his book, Dr. Navarro elaborated on the contours of his envisioned Green Bay Sweep. After learning of Dr. Navarro’s public pronouncements about the 2020 election and the events leading up to the January 6th riot, counsel to the Select Committee informed Dr. Navarro in writing that the Select Committee would seek his deposition testimony and documents relevant to the Committee’s inquiry. Counsel asked Dr. Navarro whether he would accept email service of a subpoena and whether he was represented by counsel. Three minutes later, and without even seeing the content of the subpoena, Dr. Navarro replied: “Yes. No counsel. Executive privilege.” J.A. 2646 (formatting modified).  9 Hours later, the Select Committee served its subpoena. The cover letter explained that the subpoena sought documents and testimony related to, among other things, the contents of the Navarro Report and his Green Bay Sweep theory. The letter also noted that Dr. Navarro had “already discussed these and other relevant issues in his recently published book, in interviews with reporters, and, among other places, on a podcast.” J.A. 2634 (formatting modified). The Select Committee’s subpoena ordered Dr. Navarro to appear for a deposition on March 2, 2022, and to produce a schedule of documents by February 23, 2022. That schedule included documents related to the Navarro Report, Green Bay Sweep, claims of fraud in the 2020 election, efforts to contest the results of that election, efforts to organize rallies in Washington, D.C., and the January 6th attack on the Capitol. Instructions attached to the schedule directed Dr. Navarro to compile a privilege log for any documents he intended to withhold from the Select Committee. Dr. Navarro did not produce any documents, submit a privilege log, or otherwise respond to the subpoena by February 23rd. On February 24th, the Select Committee wrote to Dr. Navarro advising him of his default and inquiring whether he planned to disregard his obligation to appear for a deposition as well. Days later, Dr. Navarro told the Select Committee that “President Trump has invoked Executive Privilege in this matter” and that his “hands [were] tied.” J.A. 2648. The Select Committee responded that its subpoena concerned topics Dr. Navarro could discuss “without raising any executive privilege concerns at all[,]” and that the Select Committee could take “additional steps to address” Dr. Navarro’s privilege assertion  10 if he stated it “on a question-by-question basis during the deposition.” J.A. 2647. Dr. Navarro’s only response was to inquire whether his deposition would “be open to the public and press[.]” J.A. 2647. When the Select Committee informed him that the deposition would be closed, but that it “would be happy to work with” Dr. Navarro to schedule the deposition at his convenience and tailor any inquiry to his assertions of privilege, Dr. Navarro simply copied and pasted his earlier message asserting executive privilege. J.A. 2647. On February 28th, the Deputy White House Counsel to then-President Joseph R. Biden Jr. wrote Dr. Navarro regarding the Select Committee’s subpoena. That letter informed Dr. Navarro that, in President Biden’s view, an assertion of executive privilege in response to the subpoena was “not justified,” and that President Biden had “decided not to assert executive privilege as [to Dr. Navarro’s] testimony regarding those subjects, or any documents” bearing on them. J.A. 791. The letter also advised that President Biden had decided not to “assert immunity to preclude [Dr. Navarro] from testifying before the Select Committee.” J.A. 791. Dr. Navarro did not respond. Dr. Navarro did not cure his earlier default on the subpoena’s demand for documents. And Dr. Navarro did not appear for his scheduled deposition on March 2nd. Weeks later, the Select Committee issued a report on its interactions with Dr. Navarro. H.R. REP. NO. 284, 117th Cong., 2d Sess. (2022). In relevant part, the Select Committee reported that Dr. Navarro had defaulted on its subpoena regarding topics “as to which there can be no conceivable privilege claim” based solely “on a blanket assertion of executive privilege purportedly asserted by former-President  11 Trump.” Id. at 14. The report added that there was “no evidence that former-President Trump ha[d] asserted executive privilege,” and that the sitting President had expressly declined to assert the privilege. Id. On March 28, 2022, the Select Committee unanimously recommended to the full House that it hold Dr. Navarro in contempt. A week later, the full House found Dr. Navarro in contempt and referred the matter to the U.S. Attorney for the District of Columbia for prosecution under Section 192. H.R. Res. 1037, 117th Cong., 2d Sess. (2022). B In June 2022, a grand jury indicted Dr. Navarro on two counts of contempt of Congress, in violation of Section 192. Count 1 concerns Dr. Navarro’s refusal to produce subpoenaed materials. Count 2 concerns Dr. Navarro’s refusal to appear for his deposition. 1 Dr. Navarro moved to dismiss both counts of the indictment on the ground that “when a former president invokes Executive Privilege as to a senior presidential advisor, that advisor cannot thereafter be prosecuted for contempt of Congress” because a contrary rule would amount to “unconstitutional interference with the doctrine of separation of powers.” J.A. 122. The district court initially denied the motion on the ground that Dr. Navarro had not offered any factual support for his claim that President Trump had invoked executive privilege for his subpoena. United States v. Navarro, 651 F. Supp. 3d 212, 222–223 (D.D.C. 2023) (“Navarro I”). In response, Dr. Navarro repeatedly requested that the court hold an evidentiary hearing to determine whether  12 President Trump had invoked executive privilege. The district court subsequently conducted the requested hearing. See United States v. Navarro, No. 22-cr-200, 2023 WL 4846715, at *1 (D.D.C. July 28, 2023). Dr. Navarro testified to an informal “protocol” of directing inquiries regarding whether to assert executive privilege to a personal aide to former President Trump, Elizabeth Harrington, who would relay those requests to the President. Dr. Navarro claimed to have “initiated the protocol” by contacting Ms. Harrington after receiving the Select Committee’s subpoena. Aug. 28, 2023, Hr’g Tr., ECF No. 148, at 59:8–17. He also testified that he subsequently had a three-minute phone conversation with President Trump in which “it was very clear that the privilege was invoked, very clear.” Id. at 63:25–64:16. Dr. Navarro submitted phone records corroborating the phone call’s timeline, but he failed to produce any document establishing that President Trump had directed him to assert executive privilege and could not recall whether such a document existed. See id. at 91:6–16. Dr. Navarro also submitted a letter, written after the district court had initially denied his motion to dismiss, from Evan Corcoran, counsel to President Trump, “confirm[ing] President Trump’s position that, as one of his senior advisors, [Dr. Navarro] had an obligation to assert executive privilege on his behalf[.]” J.A. 2360–2361. Other documentary evidence showed that when Dr. Navarro had received a different subpoena from a different committee, counsel to President Trump had sent emails stating that “POTUS wants to exert executive privilege over this subpoena[,]” J.A. 2233; President Trump also had publicly directed “Peter Navarro to protect executive privilege” in response to that other subpoena, J.A. 2235; and Dr. Navarro had relayed that written directive to the relevant committee.  13 The government submitted transcripts of Ms. Harrington’s grand jury testimony in which she recalled Dr. Navarro contacting her about the possibility of asserting executive privilege in response to the Select Committee’s subpoena, but she could not recall ever bringing the matter to President Trump’s attention or directing Dr. Navarro to invoke the privilege. Justin Clark, another attorney to President Trump, also testified to the grand jury that, although he was personally involved in sending letters formally asserting executive privilege for other Select Committee subpoenas, he was aware of no such formal assertion as to the Select Committee’s subpoena to Dr. Navarro. The district court denied Dr. Navarro’s motion to dismiss. The court concluded, as a matter of law, that an assertion of executive privilege requires the following: (1) The “privilege must be claimed by the President or an official authorized to speak for the President”; (2) the privilege assertion must come after “some level of personal consideration” by the President; and (3) the assertion must be “by some affirmative act or conduct” rather than “by mere acquiescence[.]” Aug. 30, 2023, Hr’g Tr., ECF No. 149, at 11:2–13:6. The court then found, as a matter of fact, that Dr. Navarro had not come forward with evidence showing that any such claim of privilege regarding the Select Committee’s subpoena had been made by the President or a designee. See Aug. 30, Hr’g Tr. at 14:7–25:20. Finally, the court concluded that because President Trump had not invoked executive privilege, Dr. Navarro’s separation-of-powers defense premised on that invocation necessarily failed. Separately, the government moved in limine to preclude Dr. Navarro from presenting at trial any argument or evidence that he believed in good faith that executive privilege shielded  14 his noncompliance with the Select Committee’s subpoena. The district court granted that motion over Dr. Navarro’s objection, concluding that this court’s precedent “forecloses a defense premised solely on [Dr. Navarro’s] claimed belief that President Trump’s invocation of executive privilege excused” his default. Navarro I, 651 F. Supp. 3d at 238 (citing Licavoli v. United States, 294 F.2d 207 (D.C. Cir. 1961)). Consistent with that ruling, and over Dr. Navarro’s objection, the district court instructed the jury that Dr. Navarro’s “understanding or belief that executive privilege excused him from complying” with the Select Committee’s subpoena was “not a defense to contempt of Congress[.]” Jury Instr., ECF No. 133, at 10. 2 In September 2023, after a two-day trial, a jury found Dr. Navarro guilty on both counts of contempt of Congress. The district court subsequently sentenced Dr. Navarro to concurrent four-month terms of imprisonment on each count. Dr. Navarro promptly noticed his appeal. This court denied Dr. Navarro’s motion for release pending appeal. Per Curiam Order, No. 24-3006, Dkt. 2044905 (March 14, 2024). The Supreme Court did the same. Navarro v. United States, 144 S. Ct. 771 (2024) (Roberts, C.J., in chambers). Dr. Navarro completed his sentence in July 2024. Meanwhile, Dr. Navarro continued to press his appeal challenging his conviction. After the appeal had been fully briefed, and after granting the government’s unopposed request for a lengthy extension of time to reconsider its position following a change in administrations, this court directed the government to report whether it “wishe[d] to continue to prosecute this criminal appeal or to have it dismissed.” Per  15 Curiam Order, No. 24-3006, Dkt. 2109960 (Apr. 8, 2025). The government chose neither option and, instead, moved to strike its own brief on the ground “that it is no longer taking the same position as the prior administration in this case.” Gov’t’s Mot., No. 24-3006, Dkt. 2132720 (Aug. 29, 2025). It did not move to dismiss the appeal or to file a different brief. We granted the government’s motion, struck its brief from the record, and proceeded to oral argument with Dr. Navarro alone, explaining that “the government is deemed to have withdrawn from any further participation in this appeal.” Per Curiam Order, No. 24- 3006, Dkt. 2137545 (Sept. 29, 2025). III The district court had jurisdiction under 18 U.S.C. § 3231. We have jurisdiction over Dr. Navarro’s timely appeal under 28 U.S.C. § 1291. Dr. Navarro’s completion of his sentence does not moot his appeal. See United States v. Juvenile Male, 564 U.S. 932, 936 (2011). IV Dr. Navarro first challenges the district court’s denial of his motion to dismiss the indictment on separation-of-powers grounds. We review questions of constitutional law de novo. United States v. Nassif, 97 F.4th 968, 973 (D.C. Cir. 2024). We review the district court’s factual findings for clear error. United States v. Bryant, 111 F.4th 105, 108 (D.C. Cir. 2024). Dr. Navarro contends that the district court’s factual findings resolved “mixed questions” of law and fact such that we owe the district court’s decision only due deference. See United States v. Kim, 23 F.3d 513, 517 (D.C. Cir. 1994). That is incorrect. The district court’s factual findings and legal conclusions are analytically distinct and were announced  16 separately. Dr. Navarro recognized as much before the district court. In seeking an evidentiary hearing, he argued expressly that “whether the former President in fact directed Dr. Navarro to assert the presidential privilege on his behalf is a question of fact[.]” J.A. 819. This court reviews factual findings relevant to an asserted claim of privilege for clear error. See FTC v. Boehringer Ingelheim Pharms., Inc., 892 F.3d 1264, 1267 (D.C. Cir. 2018). A The questions before this court are narrowed considerably due to three admissions made by Dr. Navarro. First, Dr. Navarro concedes that the district court, rather than a jury, was responsible for deciding whether executive privilege had been invoked and whether such invocation excused his default. See Nov. 4, 2022, Hr’g Tr., ECF No. 64, at 10:11–12 (“[T]here needs to be an evidentiary proceeding[.]”); J.A. 608–609 (moving the district court to “hold an evidentiary hearing”); see generally Opening Br. (raising no challenge to the district court’s procedure). Second, Dr. Navarro agrees that executive privilege must be affirmatively invoked on a subpoena-by-subpoena basis and does not arise automatically or by implication. See Nov. 4, Hr’g Tr. at 73:6–9 (“[T]his does come down to whether or not President Trump instructed Dr. Navarro to invoke executive privilege.”); Aug. 28, Hr’g Tr. at 97:1–8 (agreeing that “an invocation as to one subpoena does not apply to a different subpoena”); Oral Arg. Tr. 9:22–10:12 (reaffirming before this court that his “position in district court” was that there must be a “subpoena specific invocation of privilege,” and stating that “still is” his position on appeal).  17 Third, Dr. Navarro admits that at least some of the information sought by the subpoena pertains to statements in his privately published and publicly released three-volume Navarro Report, his book published after he left the government, and his multiple public talks, none of which are protected by executive privilege. See J.A. 962 (conceding before the district court that the Select Committee’s subpoena sought “non-official/personal documents”); Oral Arg. Tr. 23:20–24:1 (conceding before this court that he could not make “any argument” that information about his public statements or publications are privileged). Dr. Navarro’s concessions are well founded. To start, this court has long recognized that a “trial court faced with a pretrial motion to dismiss the indictment because of immunity granted by Federal or State Governments * * * can hold a pretrial evidentiary hearing” to resolve that claim. United States v. De Diego, 511 F.2d 818, 823–824 (D.C. Cir. 1975); see also United States v. Bulger, 816 F.3d 137, 146 (1st Cir. 2016) (“[O]ur across-the-board research suggests that resolving a defendant’s claim that he is immune from prosecution pretrial, as opposed to at trial, is more the norm than the exception.”). In addition, the Supreme Court has said directly that executive privilege must be invoked. See, e.g., Cheney, 542 U.S. at 389 (“Executive privilege is an extraordinary assertion of power not to be lightly invoked. Once executive privilege is asserted, coequal branches of government are set on a collision course.”) (formatting modified); United States v. Nixon, 418 U.S. at 713 (“If a President concludes that compliance with a subpoena would be injurious to the public interest[,] he may * * * invoke a claim of privilege[.]”). This court has too. In re Sealed Case, 121 F.3d at 744 (“The President can invoke the [presidential communications] privilege when asked to produce documents[.]”); Thompson,  18 20 F.4th at 26 (describing the President’s “right to assert executive privilege”). To be sure, we have referred to the presidential communications privilege as a “presumptive” protection. E.g., Dellums v. Powell, 561 F.2d 242, 246 (D.C. Cir. 1977). But the term “presumptive” denotes only that the privilege is qualified and may be overcome—not that it springs into effect immediately and spontaneously regardless of what a President might choose. See United States v. Nixon, 418 U.S. at 713–714 (Once the President “invoke[s] a claim of privilege on the return of [a] subpoena[,]” a court must determine whether the party seeking the information has “made a sufficient showing to rebut the presumption” of privilege.); In re Sealed Case, 121 F.3d at 744 (“If the President [invokes the privilege], the documents become presumptively privileged.”). Finally, the law is settled that executive privilege extends only to the provision of confidential advice by select presidential advisers; it does not apply to public statements or matters discussed in a personal capacity. See, e.g., Mazars, 140 S. Ct. at 2032–2033; In re Sealed Case, 121 F.3d at 752. B Against that backdrop, we reject Dr. Navarro’s separation- of-powers defense. The separation-of-powers problem that Dr. Navarro asserts depends on there being a clash between the Executive’s invocation of privilege and Congress’s enforcement of its subpoena for the assertedly privileged material. See Opening Br. 13. No such clash occurred here. We hold that the authority to invoke executive privilege rests with a president or his designee. In that regard, the district court did not clearly err in finding as a matter of fact that neither President Trump nor a designee invoked executive privilege as  19 to the Select Committee’s subpoena to Dr. Navarro. Dr. Navarro’s executive-privilege claim also fails for the independent reason that he defaulted on his obligation to produce documents and testimony that could not have been subject to executive privilege at all. As a result, Dr. Navarro’s separation-of-powers defense falls apart. 1 The district court had authority to resolve whether executive privilege had been invoked as to the Select Committee’s subpoena to Dr. Navarro. And it correctly concluded that only the President or his designee could invoke the privilege. a Dr. Navarro mounts two threshold challenges to the district court’s authority to resolve the privilege issues in this case, both of which reason that the Judicial Branch’s involvement in this suit itself amounts to a violation of the separation of powers. Those arguments fail. First, Dr. Navarro argues that federal courts cannot decide at all whether executive privilege has been invoked. Opening Br. 36. Not so. As the Supreme Court has held, “it is the province and duty of this Court ‘to say what the law is’ with respect to the claim of privilege presented[.]” United States v. Nixon, 418 U.S. at 705 (quoting Marbury v. Madison, 5 U.S. (1 Cranch) 137, 177 (1803)); accord Committee on the Judiciary, U.S. House of Representatives v. McGahn, 968 F.3d 755, 769 (D.C. Cir. 2020) (en banc) (In adjudicating a claim of testimonial immunity, the court “does not arrogate any new power to itself at the expense of either of the other branches but rather plays its appropriate constitutional role[.]”).  20 To get around that precedent, Dr. Navarro retreats to arguing that a court cannot prescribe how executive privilege may be invoked. Opening Br. 33. That cannot be right. To start, there is no relevant daylight between deciding whether privilege has been invoked (which our precedent allows) and how its invocation can be evidenced. A court, after all, could never hold that privilege was not invoked without identifying a basis for that conclusion grounded in what the law requires for an invocation of privilege and whether such an invocation was demonstrated as a factual matter. Anyhow, drawing the line at the “how” of privilege invocations would be an odd result. The Judiciary is no stranger to disputes over executive privilege. When necessary, this court has repeatedly established criteria pertaining to the who, what, and when of executive privilege invocations before. See, e.g., In re Sealed Case, 121 F.3d at 751–752 (holding that “communications made by presidential advisers in the course of preparing advice for the President come under the presidential communications privilege, even when these communications are not made directly to the President”); Judicial Watch, Inc. v. Department of Justice, 365 F.3d 1108, 1112 (D.C. Cir. 2004) (holding that “the principles underlying the presidential communications privilege limit its reach to documents and other communications ‘solicited and received’ by the Office of the President, and thus do not extend to agency documents that are not submitted for Presidential consideration”). Likewise, the Supreme Court has intervened to determine whether even an indisputably valid assertion of executive privilege can prevail over the competing need for privileged material in a criminal case. See United States v. Nixon, 418 U.S. at 713 (An “assertion of privilege must yield to the demonstrated, specific need for evidence in a pending criminal trial.”).  21 Nor does judicial scrutiny of the form of executive privilege’s invocation carry any distinct separation-of-powers baggage. The Supreme Court has prescribed the terms under which the Executive can invoke the analogous state secrets privilege. See Reynolds, 345 U.S. at 7–8 (“There must be [a] formal claim of privilege, lodged by the head of the department which has control over the matter, after actual personal consideration by that officer.”) (footnotes omitted). So too for how Congress can invoke its legislative subpoena power. See Mazars, 140 S. Ct. at 2031–2032. Courts, after all, could not discharge their Article III adjudicatory function if forced to accept at face value mere claims of executive privilege put forth by any employee with some asserted presidential advisory role. See United States v. Nixon, 418 U.S. at 712 (“[T]he allowance of the privilege to withhold evidence that is demonstrably relevant in a criminal trial would * * * gravely impair the basic function of the courts.”). Equally problematically, without setting terms on how a claim of privilege can be substantiated, courts could mistakenly apply the privilege against the will of the President based solely on a defendant’s say-so. But an Article III court cannot exercise an authority to invoke privilege that is vested exclusively in the President. And without requiring proof of the privilege’s proper assertion, a court would risk stepping into the Executive’s domain. A court, in other words, cannot simply take a defendant at his word that the President invoked privilege because doing so would impermissibly tangle separation-of-powers lines. Second, Dr. Navarro objects that, at a minimum, courts must require the Political Branches “to seek accommodation  22 through good faith negotiations” over a privilege claim before weighing in. Opening Br. 27. That contention is to no avail. To be sure, efforts at accommodation are the preferred approach in interbranch disputes. See Mazars, 140 S. Ct. at 2031 (extolling the “tradition of negotiation and compromise” between Congress and the President over subpoenas for the President’s personal papers); United States v. American Tel. & Tel. Co., 567 F.2d 121, 127 (D.C. Cir. 1977) (“[E]ach branch should take cognizance of an implicit constitutional mandate to seek optimal accommodation through a realistic evaluation of the needs of the conflicting branches in the particular fact situation.”). But as it turns out, the Political Branches are entirely in accord this time. Congress held Dr. Navarro in contempt. And the Executive both informed Dr. Navarro that his assertion of executive privilege was unjustified and exercised its exclusive authority to bring this prosecution. So this case does not confront the court with an interbranch conflict. See Thompson, 20 F.4th at 37. In addition, extensive efforts at accommodation occurred. The Select Committee afforded then-former President Trump ample opportunity to invoke executive privilege if he so chose. The district court found that, before this case began, President Trump had notice both of the Select Committee’s subpoena to Dr. Navarro and the Committee’s determination that he was not protected by executive privilege. Then-former President Trump chose to remain silent on the subject. Contrast Nixon v. GSA, 433 U.S. at 430 (former president filed affirmative civil suit); Thompson, 20 F.4th at 22 (same); Dellums, 561 F.2d at 244 (former president filed motion to quash); J.A. 2235 (then- former President Trump publicly directing Dr. Navarro “to  23 protect executive privilege” in response to a different subpoena). The district court also found as fact that the Select Committee repeatedly tried to accommodate Dr. Navarro’s assertion of privilege, seeking clarification on the nature and scope of his claims and offering to discuss ways to preserve his ability to assert any appropriate privilege in response to specific questions. See Navarro I, 651 F. Supp. 3d at 226. It was Dr. Navarro who flatly refused to engage. And nothing in the separation of powers requires rewarding that behavior. Finally, this court afforded the Executive a long extension of time to reconsider the government’s position in this case and to decide whether it wished to dismiss the appeal. The government did not ask for additional time, and it chose only to strike its brief. Again, no claim of privilege was asserted. For all those reasons, we conclude the district court had the legal authority in this case, consi